Magnesium administration for vasospasm prevention in acute aneurysmal SAH: a multicenter randomized controlled trial.
Moinay Kim, Jeong Hoon Kim, Hyunchul Jung et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter randomized controlled trial investigated the effect of magnesium sulfate (MgSO₄) on cerebral vasospasm (CV) prevention in 121 patients with acute aneurysmal subarachnoid hemorrhage (aSAH). While no significant difference in overall CV incidence was observed, the magnesium group showed reduced mean flow velocity and Lindegaard ratio, indicating less severe vasospasm during days 4-9. The study highlights the potential benefits of magnesium in managing vasospasm severity.
Key findings
- No significant difference in overall CV incidence between magnesium and placebo groups.
- The magnesium group had significantly lower mean flow velocity and Lindegaard ratio on days 4-9.
- A median serum magnesium concentration >2.5 mg/dL was associated with lower risks of CV and DCI.
Why it matters
Understanding the role of magnesium in managing vasospasm could inform treatment strategies for patients with aSAH, potentially improving outcomes despite the lack of significant differences in CV incidence.